



For Immediate Release

VENTRIPOINT INSTALLS FIRST UPDATED VMS™ HEART ANALYSIS SYSTEM AT EVELINA CHILDREN'S HOSPITAL IN LONDON, UK

***** First Children's Hospital in the United Kingdom to Use the VMS™ *****

SEATTLE, WASHINGTON, February 9, 2012 – VentriPoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF.PK) is pleased to announce the installation of its upgraded VMS™ heart analysis system at Evelina Children's Hospital, which is part of Guy's and St. Thomas' NHS Foundation Trust in London, UK.

"The VMS™ is non-invasive and repeatable as compared to MRI, and we are confident in the results using routine clinical scanning", stated Dr. John Simpson, Director of the Echocardiography Laboratory at Evelina. "At Evelina, all children undergoing MRI must have a general anesthetic. This is not required for the VMS™ and is a major improvement as we will not have to subject these children to the added complexity and risk of a general anesthetic."

The VMS™ procedure utilizes standard 2D ultrasound to acquire routine heart images to monitor heart function in congenital heart disease, specifically those patients born with Tetralogy of Fallot (Blue-baby Syndrome) or Systemic Right Ventricle. Published and "in-press" clinical studies have shown that VMS™ results are the same as MRI results, but take less time and do not require anesthesia. The patient needs to remain still for only 5 minutes as compared to 60 minutes for a MRI procedure.

"Evelina is a worldwide leading institution in pediatric cardiology. We are pleased to enable its doctors to treat their patients more quickly and conveniently, while maintaining accurate medical results," said Amol Karnick, Vice-President of Sales, Marketing and Business Development for VentriPoint.

This is the first installation of the updated version of the VMS™, which has passed all final testing and is now available for purchase for clinical use in Europe and Canada, but is available for research purposes only in the United States.

The incident rate of congenital heart disease in the UK is about 3.69 per 1,000 live births. Advancements in operational procedures have allowed these children to live longer and fuller lives, but still require live-long monitoring of their right ventricles. VentriPoint continues to grow and generate excitement about the VMS™ alternative to MRI.

About Dr. Simpson

Dr. John Simpson is a Consultant in Fetal and Paediatric Cardiology specializing in advanced echocardiographic techniques and fetal cardiology. He has been a Consultant at Guy's and St Thomas' NHS Foundation Trust in central London since 1998. Dr. Simpson is Director of Paediatric Echocardiography at the Evelina Children's Hospital which is part of Guy's and St Thomas'. He has published over 100 papers in the field of congenital heart disease and has contributed chapters to the leading textbooks of three-dimensional echocardiography, congenital echocardiography and fetal cardiology. Dr Simpson also cares for babies and children with congenital heart disease after birth.

About Evelina Children's Hospital

The Department of Congenital Heart Disease at the Evelina Children's Hospital has an international reputation in all aspects of diagnosis and treatment of patients of all age groups with heart problems from the fetus to adult life. There are approximately 6,000 patients/year under its care. The Hospital performs about 10,000 echocardiographies and electrocardiograms each year. The Paediatric Cardiology ward contains 18 beds, including four cubicles for children with infections that may need isolation, or children who need special precautions. Patients from all over the world come here to be treated for their heart condition. In the Department of Paediatric Cardiology, between 450-500 operations on congenital heart disease are carried out annually by its surgeons. Evelina Children's Hospital is part of Guy's and St Thomas' NHS Foundation Trust.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

VentriPoint Diagnostics Ltd.
Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com

Howard Group Inc.
Peter Weichler/David Burwell
Telephone: 1.888-221-0915 or 403-221-0915
email: Peter@howardgroupinc.com
Dave@howardgroupinc.com

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this

document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release